Publicaciones (301) Publicaciones de Juan Jesús Cruz Hernández

2024

  1. Biología celular y molecular del cáncer

    Oncología clínica (Arán Ediciones), pp. 13-23

  2. Diagnóstico nosológico y de extensión. Factores pronósticos

    Oncología clínica (Arán Ediciones), pp. 59-71

  3. Epidemiología del cáncer. Factores de riesgo y carcinogénesis

    Oncología clínica (Arán Ediciones), pp. 25-42

  4. Oncología clínica coord.

    Arán Ediciones

  5. Tumores de origen desconocido

    Oncología clínica (Arán Ediciones), pp. 407-418

2023

  1. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

  2. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  3. Multimodal Physical Exercise and Functional Rehabilitation Program in Oncological Patients with Cancer-Related Fatigue—A Randomized Clinical Trial

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 6

  4. Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

  5. Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2

    Reumatologia clinica, Vol. 19, Núm. 2, pp. 121

2022

  1. Acute esophageal necrosis induced by immune checkpoint inhibitors

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 3, pp. 182-183

  2. Adaptation and validation of the Spanish version of the everyday cognition battery for assessing everyday cognition in older adults

    BMC Geriatrics, Vol. 22, Núm. 1

  3. Cardiac magnetic resonance to detect different patterns of myocardial injury in patients receiving immune checkpoint inhibitors

    Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 266-269

  4. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

    European Urology Focus, Vol. 8, Núm. 6, pp. 1673-1682

  5. Epidemiological Study of Prostate Cancer in the Province of Salamanca (2006-2015)

    Archivos espanoles de urologia, Vol. 75, Núm. 7, pp. 630-637

  6. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  7. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

  8. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

    Oral Oncology, Vol. 134

2021

  1. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab

    Reumatologia Clinica, Vol. 17, Núm. 10, pp. 559-561

  2. Biomarcadores moleculares y celulares. Implicaciones en la terapia dirigida

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 25, pp. 1418-1423